Olaparib shows promise in kidney cancer subtype
The PARP inhibitor olaparib demonstrated antitumor activity in patients with BAP1-mutated renal cell carcinoma.
Related Articles
TRANSFORM trial to evaluate screening methods in prostate cancer
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
Innovation fund to bolster adoption of prostate cancer test
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
Medicare’s G2211 and thoughts on how to best use it in urology
“We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and…
Study identifies method to reduce extended-spectrum antibiotic use for UTI
“Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the…
Gem-doce and BCG yield similar outcomes for upper tract urothelial cell carcinoma
“Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel…
Study progresses of NK cell therapy in mCRPC
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study…
Conference
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Dr. Sohi on the future of PSMA-PET imaging in prostate cancer
Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer.
Expert on future directions for targeted therapy in urothelial carcinoma
“There is great interest in looking at all these targeted interventions in the earlier stages to lower the burden of care that patients go through…
Real-world data support safety, efficacy of Aquablation for BPH-related LUTS
“The results showed the contemporary Aquablation procedural safety in Japanese men is exceptional in a broad range of prostate sizes along with significant symptom reduction,”…